


AMENDMENTS TO THE CLAIMS

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (previously presented): A triaza-cyclopenta[cd]indene derivative represented by the following formula [I]:



(wherein R¹ and R² are the same or different, and independently are hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl, C₁₋₆alkoxy-C₁₋₆alkyl, hydroxy-C₁₋₆alkyl, cyano-C₁₋₆alkyl, carbamoyl-C₁₋₆alkyl or di(C₁₋₆alkyl)amino-C₁₋₆alkyl, cyano, carbamoyl or aryl;

R³ is hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl, halogen, C₁₋₆alkoxy, C₃₋₇cycloalkyloxy, C₁₋₆alkylthio or -N(R⁶)R⁷;

R⁴ is hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl or C₃₋₇cycloalkyl-C₁₋₆alkyl;

R⁵ is hydrogen, C₁₋₆alkyl, aryl-C₁₋₆alkyl or carbamoyl;

Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C₁-6alkyl, C₃-7cycloalkyl, C₂-6alkenyl, C₂-6alkynyl, C₁-6alkoxy, C₁-6alkylthio, C₁-6alkylsulfinyl, C₁-6alkylsulfonyl, cyano, nitro, hydroxy, -CO₂R⁸, -C(=O)R⁹, -CONR¹⁰R¹¹, -OC(=O)R¹², -NR¹³CO₂R¹⁴, -S(=O)_rNR¹⁵R¹⁶, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy and -N(R¹⁷)R¹⁸;

R⁸ and R¹⁴ are the same or different, and independently are hydrogen or C₁-5alkyl, C₃-8cycloalkyl, C₃-8cycloalkyl-C₁-5alkyl, aryl or aryl-C₁-5alkyl;

R⁶, R⁷, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁵, R¹⁶, R¹⁷ and R¹⁸ are the same or different, and independently are hydrogen, C₁-6alkyl or C₃-7cycloalkyl;

r is 1 or 2;

or individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

2. (original): The triaza-cyclopenta[cd]indene derivative according to claim 1 represented by the formula [I], wherein R³ is C₁-6alkyl; R⁴ is hydrogen or C₁-6alkyl; R⁵ is hydrogen or C₁-6alkyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C₁-3alkyl, C₁-3alkoxy, C₁-3alkylthio, trifluoromethyl, trifluoromethoxy and -N(R¹⁷)R¹⁸ (wherein R¹⁷ and R¹⁸ are the same or different, and independently are hydrogen or C₁-3alkyl); R¹, R² and R⁴ are as defined in claim 1, or pharmaceutically acceptable salts and hydrates thereof.

3. (original): The triaza-cyclopenta[cd]indene derivative according to claim 1 represented by the formula [I], wherein R³ is C₁₋₃alkyl; R⁵ is hydrogen or C₁₋₃alkyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C₁₋₃alkyl; R¹, R² and R⁴ are as defined in claim 1, or pharmaceutically acceptable salts and hydrates thereof.

4. (currently amended): A composition comprising a triaza-cyclopenta[cd]indene derivative, a pharmaceutically acceptable salt thereof or its hydrate according to claim 1, as an active ingredient and a pharmaceutically acceptable carrier.

5. (previously presented): A method for treating depression or anxiety comprising administering to a patient in need of treatment a pharmaceutically effective amount of the triaza-cyclopenta[cd]indene derivative, a pharmaceutically acceptable salt thereof or its hydrate according to claim 1.